logo
Twitter
Discord
Email
logo
LifeMD, Inc.

LifeMD, Inc.

NASDAQ•LFMD
CEO: Mr. Justin Schreiber
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Listing Date: 2008-01-29
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
Contact Information
236 Fifth Avenue, Suite 400, New York, NY, 10001, United States
866-351-5907
lifemd.com
Market Cap
$181.47M
P/E (TTM)
-37.8
252
Dividend Yield
--
52W High
$15.84
52W Low
$3.18
52W Range
5%
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$60.17M+49.40%
4-Quarter Trend

EPS

-$0.10-29.07%
4-Quarter Trend

FCF

$6.42M+136.93%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Telehealth Revenue Strong Growth Telehealth revenue reached $147.2M for nine months, marking a 34% increase compared to prior year period.
Total Revenue Increased 25% Total net revenues were $187.0M for nine months ended September 30, 2025, showing 25% growth.
Gross Profit Margin Improvement Gross profit grew 9% to $52.8M for the quarter, supported by increased telehealth subscription demand.

Risk Factors

Working Capital Deficit Persists Working capital deficit reached $(15.6M) as of September 30, 2025, driven by cash usage for debt repayment.
Significant Legal Contingencies Multiple shareholder class action and derivative complaints filed in late 2025 regarding business conduct and disclosures.
Accumulated Deficit Widens Accumulated deficit reached $(247.8M) as of September 30, 2025, reflecting cumulative net losses since inception.

Outlook

Focus on Pure-Play Telehealth Sold majority WorkSimpli interest in November 2025 to focus on scaling virtual care and pharmacy operations.
Cash Sufficient for Twelve Months Existing cash balance of $23.8M is expected to fund planned operating and capital expenditures for next 12 months.
Expanding Weight Management Access Launched GLP-1 program expansion and secured pathways for Zepbound and Ozempic access for patients.

Peer Comparison

Revenue (TTM)

High Tide Inc.HITI
$407.32M
+11.2%
TruBridge, Inc.TBRG
$349.88M
+3.6%
LifeMD, Inc.LFMD
$252.34M
+40.2%

Gross Margin (Latest Quarter)

AC Immune SAACIU
100.0%
+0.0pp
Sanara MedTech Inc.SMTI
92.9%
+2.1pp
LifeMD, Inc.LFMD
87.7%
-32.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CERS$499.43M-31.2-27.9%45.6%
SLP$409.58M-6.4-45.5%0.4%
RXST$403.35M-11.2-12.8%3.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.2%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Mar 9, 2026
|
EPS:-$0.01
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 17, 2025|
    Revenue: $60.17M+49.4%
    |
    EPS: $-0.10-29.1%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $62.22M+22.8%
    |
    EPS: $-0.06-62.2%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $65.70M+48.8%
    |
    EPS: $0.01-105.9%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 11, 2025|
    Revenue: $212.45M+39.3%
    |
    EPS: $-0.53+24.3%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $40.28M+4.3%
    |
    EPS: $-0.14-22.2%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $50.66M+40.9%
    |
    EPS: $-0.17-19.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $44.14M+33.3%
    |
    EPS: $-0.17-46.9%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 11, 2024|
    Revenue: $152.55M+28.2%
    |
    EPS: $-0.70+51.7%
    Miss